On The Pen With Dave Knapp

المدة الإجمالية:29 h 20 min
Compound Tirzepatide Lawsuit + PBM Reform Update // OTP TWD 5.6.25
On The Pen With Dave Knapp
26:31
CVS Drops Zepbound + Lilly Earnings Call Recap
On The Pen With Dave Knapp
33:37
Compound GLP-1 PubMed Data: What It Didn’t Tell Us
On The Pen With Dave Knapp
21:40
High Dose Semaglutide Incoming! How Much Will it Cost? // OTP TWD 4.22.25
On The Pen With Dave Knapp
18:45
Getting Insurance To Cover Skin Removal Surgery // OTP Eps 109
On The Pen With Dave Knapp
64:02
Counterfeit Ozempic at Pharmacies! // OTP TWD 4.15.25
On The Pen With Dave Knapp
14:43
GLP-1 Slow Responders: Dr Matthea Rentea // OTP Eps 108
On The Pen With Dave Knapp
68:01
Grow-Zempic!? These Students Discoverd a GLP-1 Plant!
On The Pen With Dave Knapp
19:08
Noom CEO Geoff Cook Interview: Wall Street Journal GLP-1 Cost Ad
On The Pen With Dave Knapp
27:58
GLP-1 Medicare Coverage: What is Going On // OTP TWD 04.08.2025
On The Pen With Dave Knapp
25:41
Are GLP-1 Meds For Life? Fractyl’s CEO Says “Not So Fast!”
On The Pen With Dave Knapp
27:35
Fake Sugar: 👍 or 👎 for Weight Loss With Dr. Spencer Nadolsky // OTP Eps 107
On The Pen With Dave Knapp
57:06
Tirzepatide Compounds: Lilly Sues Pharmacies // OTP TWD 04.01.25
On The Pen With Dave Knapp
37:06
Zepbound Weight Loss Stalls: Tips and Tricks // OTP Eps 106
On The Pen With Dave Knapp
64:36
Rare Exclusive Interview: OFA Chairman Sits Down with OTP to Talk Tirzepatide Lawsuit
On The Pen With Dave Knapp
32:20
Novo’s Retatrutide Competitor
On The Pen With Dave Knapp
27:37
Ozempic: Setting the Microdosing Strategy Straight w/ Dr Tyna Moore // OTP EPS 105
On The Pen With Dave Knapp
53:14
Compound Tirzepatide Latest // Cagrisema Disappoints Again // Great Vikingtide News
On The Pen With Dave Knapp
21:10
Obesity Bias in Medicine With Dr. Toomer // OTP Eps 104
On The Pen With Dave Knapp
90:27
Compound GLP-1 Accessibility + World Obesity Day // OTP TWD 03.04.25
On The Pen With Dave Knapp
32:10
Compound Tirzepatide Latest Updates // @Mike.OnAMssion2 Joins // OTP Eps 103
On The Pen With Dave Knapp
76:22
Lilly Drops Zepbound Price, Compounders Sue FDA (again) OTP TWD 2.25.25
On The Pen With Dave Knapp
22:31
Compound Tirzepatide Lawsuit Update / GLP-1 Heart Health w Dr Simin Lee / OTP Eps 102
On The Pen With Dave Knapp
83:25
503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25
On The Pen With Dave Knapp
23:05
Zepbound Weight Loss and Cancer Diagnosis // OTP Eps 101
On The Pen With Dave Knapp
90:22
Lilly Announces Next Gen Tirzepatide
On The Pen With Dave Knapp
30:52
GLP-1 Talk Show: An Emotional 100th On The Pen Live
On The Pen With Dave Knapp
73:37
Zepbound and Retatrutide News: Lilly Q4 Earnings Call Recap
On The Pen With Dave Knapp
33:03
Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications
On The Pen With Dave Knapp
36:47
Like Retatrutide But In A Pill? OTP TWD 2.4.25
On The Pen With Dave Knapp
24:02
463 Pound Zepbound Weight Loss // OTP Eps 99
On The Pen With Dave Knapp
89:05
503b Compounder Rocked by FDA Audit + OFA v FDA Trial Update
On The Pen With Dave Knapp
20:02
Kelly Matthew of GLP1 Real Talk Joins! OTP Eps 97
On The Pen With Dave Knapp
88:08
Massive Zepbound and Wegovy News // OTP TWD 1.21.25
On The Pen With Dave Knapp
20:55
TikTok GLP-1 Refugees Episode
On The Pen With Dave Knapp
64:33
Compounders Win Small Battle in War Over Zepbound and Mounjaro Shortages
On The Pen With Dave Knapp
25:11
Legal Expert: Compound Tirzepatide Trial Update || OTP Eps 96
On The Pen With Dave Knapp
104:16
Generic Liraglutide and GLP-1 Accessibility
On The Pen With Dave Knapp
23:51
More Generic GLP-1 Options Hit The Market!
On The Pen With Dave Knapp
41:24
On The Pen: The Weekly Dose 12.17.24
On The Pen With Dave Knapp
25:46